Udari N. Colombage , Sze-Ee Soh , Kuan-Yin Lin , Amanda Vincent , Michelle White , Jane Fox , Helena C. Frawley
{"title":"伴或不伴乳腺癌的女性尿失禁的患病率和性功能障碍的严重程度:一项匹配对照研究","authors":"Udari N. Colombage , Sze-Ee Soh , Kuan-Yin Lin , Amanda Vincent , Michelle White , Jane Fox , Helena C. Frawley","doi":"10.1016/j.contre.2022.100012","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction:</h3><p>Symptoms of either female sexual dysfunction (FSD) or urinary incontinence (UI) after breast cancer treatment are reported to be common. Despite this, the prevalence and severity of FSD in women who experience UI after breast cancer treatment has not been investigated. The aim of this study was to compare the prevalence and severity of FSD in women with and without breast cancer who experience UI.</p></div><div><h3>Methods:</h3><p>A secondary analysis of data from a larger cross-sectional study was undertaken. 21 pairs of sexually active women with and without breast cancer who experienced UI were matched according to age, body-mass index and parity. The severity of FSD was assessed using the Female Sexual Function Index (FSFI). Participant demographics, prevalence of FSD, and FSFI scores were reported descriptively. Differences in prevalence rate of FSD and FSFI scores between women with and without breast cancer and UI were analysed using Wilcoxon signed-rank or McNemar’s tests.</p></div><div><h3>Results:</h3><p>Participants with breast cancer who experienced UI reported significantly higher rates of FSD (<span><math><mi>n</mi></math></span>\n<span><math><mo>=</mo></math></span> 19/21, 90%) compared to participants without breast cancer with UI (<span><math><mi>n</mi></math></span>\n<span><math><mo>=</mo></math></span> 10/21, 48% <em>p</em> <span><math><mo>=</mo></math></span> 0.0028). Participants with breast cancer and UI had a significantly lower overall FSFI score (median <span><math><mo>=</mo></math></span> 18.8, IQR <span><math><mo>=</mo></math></span> 12.5) compared to those without breast cancer with UI (median <span><math><mo>=</mo></math></span> 25.9, IQR <span><math><mo>=</mo></math></span> 10, <em>p</em> <span><math><mo>=</mo></math></span> 0.0096). They also reported lower arousal, less lubrication, lower satisfaction and more pain during sexual activity compared to participants without breast cancer who experienced UI.</p></div><div><h3>Conclusion:</h3><p>Participants with breast cancer who experienced UI had a higher prevalence and severity of FSD than participants without breast cancer with UI. They reported having lower arousal, lubrication, satisfaction and more pain during sexual activity. These preliminary results suggest larger studies to investigate sexual function in women with breast cancer and UI are warranted.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772974522000072/pdfft?md5=b0b891dd818fe2eb2710ecd21bd8ad3f&pid=1-s2.0-S2772974522000072-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Prevalence and severity of sexual dysfunction in women experiencing urinary incontinence with and without breast cancer: A matched control study\",\"authors\":\"Udari N. Colombage , Sze-Ee Soh , Kuan-Yin Lin , Amanda Vincent , Michelle White , Jane Fox , Helena C. Frawley\",\"doi\":\"10.1016/j.contre.2022.100012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction:</h3><p>Symptoms of either female sexual dysfunction (FSD) or urinary incontinence (UI) after breast cancer treatment are reported to be common. Despite this, the prevalence and severity of FSD in women who experience UI after breast cancer treatment has not been investigated. The aim of this study was to compare the prevalence and severity of FSD in women with and without breast cancer who experience UI.</p></div><div><h3>Methods:</h3><p>A secondary analysis of data from a larger cross-sectional study was undertaken. 21 pairs of sexually active women with and without breast cancer who experienced UI were matched according to age, body-mass index and parity. The severity of FSD was assessed using the Female Sexual Function Index (FSFI). Participant demographics, prevalence of FSD, and FSFI scores were reported descriptively. Differences in prevalence rate of FSD and FSFI scores between women with and without breast cancer and UI were analysed using Wilcoxon signed-rank or McNemar’s tests.</p></div><div><h3>Results:</h3><p>Participants with breast cancer who experienced UI reported significantly higher rates of FSD (<span><math><mi>n</mi></math></span>\\n<span><math><mo>=</mo></math></span> 19/21, 90%) compared to participants without breast cancer with UI (<span><math><mi>n</mi></math></span>\\n<span><math><mo>=</mo></math></span> 10/21, 48% <em>p</em> <span><math><mo>=</mo></math></span> 0.0028). Participants with breast cancer and UI had a significantly lower overall FSFI score (median <span><math><mo>=</mo></math></span> 18.8, IQR <span><math><mo>=</mo></math></span> 12.5) compared to those without breast cancer with UI (median <span><math><mo>=</mo></math></span> 25.9, IQR <span><math><mo>=</mo></math></span> 10, <em>p</em> <span><math><mo>=</mo></math></span> 0.0096). They also reported lower arousal, less lubrication, lower satisfaction and more pain during sexual activity compared to participants without breast cancer who experienced UI.</p></div><div><h3>Conclusion:</h3><p>Participants with breast cancer who experienced UI had a higher prevalence and severity of FSD than participants without breast cancer with UI. They reported having lower arousal, lubrication, satisfaction and more pain during sexual activity. These preliminary results suggest larger studies to investigate sexual function in women with breast cancer and UI are warranted.</p></div>\",\"PeriodicalId\":100330,\"journal\":{\"name\":\"Continence Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772974522000072/pdfft?md5=b0b891dd818fe2eb2710ecd21bd8ad3f&pid=1-s2.0-S2772974522000072-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Continence Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772974522000072\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Continence Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772974522000072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介:据报道，乳腺癌治疗后女性性功能障碍(FSD)或尿失禁(UI)的症状很常见。尽管如此，在乳腺癌治疗后经历尿失禁的妇女中，FSD的患病率和严重程度尚未得到调查。本研究的目的是比较患有乳腺癌和未患乳腺癌且经历过尿失禁的女性中FSD的患病率和严重程度。方法:对一项更大的横断面研究的数据进行二次分析。研究人员根据年龄、体重指数和胎次对21对性活跃的有或没有乳腺癌的女性进行了匹配。使用女性性功能指数(FSFI)评估FSD的严重程度。描述性地报告了参与者的人口统计、FSD的患病率和FSFI评分。使用Wilcoxon符号秩检验或McNemar检验分析患有和未患有乳腺癌和UI的妇女的FSD患病率和FSFI评分的差异。结果:与没有乳腺癌合并UI的参与者(n= 10/21, 48% p = 0.0028)相比，经历过UI的乳腺癌参与者报告的FSD发生率显著更高(n= 19/ 21,90%)。与没有乳腺癌合并UI的参与者(中位数= 25.9,IQR = 10, p = 0.0096)相比，患有乳腺癌合并UI的参与者的FSFI总分(中位数= 18.8,IQR = 12.5)显着降低。他们还报告说，与没有乳腺癌但经历过尿失禁的参与者相比，他们在性活动中性唤起更低、润滑更少、满意度更低、疼痛更多。结论:乳腺癌患者经历过尿失禁，其FSD的患病率和严重程度高于非乳腺癌患者。他们报告说，在性活动中，他们的兴奋度、润滑度、满足感和疼痛感都较低。这些初步结果表明，有必要进行更大规模的研究，调查乳腺癌和尿失禁妇女的性功能。
Prevalence and severity of sexual dysfunction in women experiencing urinary incontinence with and without breast cancer: A matched control study
Introduction:
Symptoms of either female sexual dysfunction (FSD) or urinary incontinence (UI) after breast cancer treatment are reported to be common. Despite this, the prevalence and severity of FSD in women who experience UI after breast cancer treatment has not been investigated. The aim of this study was to compare the prevalence and severity of FSD in women with and without breast cancer who experience UI.
Methods:
A secondary analysis of data from a larger cross-sectional study was undertaken. 21 pairs of sexually active women with and without breast cancer who experienced UI were matched according to age, body-mass index and parity. The severity of FSD was assessed using the Female Sexual Function Index (FSFI). Participant demographics, prevalence of FSD, and FSFI scores were reported descriptively. Differences in prevalence rate of FSD and FSFI scores between women with and without breast cancer and UI were analysed using Wilcoxon signed-rank or McNemar’s tests.
Results:
Participants with breast cancer who experienced UI reported significantly higher rates of FSD (
19/21, 90%) compared to participants without breast cancer with UI (
10/21, 48% p 0.0028). Participants with breast cancer and UI had a significantly lower overall FSFI score (median 18.8, IQR 12.5) compared to those without breast cancer with UI (median 25.9, IQR 10, p 0.0096). They also reported lower arousal, less lubrication, lower satisfaction and more pain during sexual activity compared to participants without breast cancer who experienced UI.
Conclusion:
Participants with breast cancer who experienced UI had a higher prevalence and severity of FSD than participants without breast cancer with UI. They reported having lower arousal, lubrication, satisfaction and more pain during sexual activity. These preliminary results suggest larger studies to investigate sexual function in women with breast cancer and UI are warranted.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
